Beth Faiman, PhD, MSN, APN-BC

The panel provides key takeaways on the most impactful innovations shaping the future of multiple myeloma treatment.

The panel provides clinical advice on caring for patients with multiple myeloma who are treated with talquetamab.

Beth Faiman, PhD, MSN, explores how a GPRC5D-targeting bispecific antibody can benefit patients with relapsed/refractory multiple myeloma.

Experts explore strategies to effectively manage toxicities associated with talquetamab in the treatment of multiple myeloma.

Experts discuss best practices for educating patients with multiple myeloma on the adverse effects associated with talquetamab treatment.

This session explores clinical evidence for sequencing treatments in MM, highlighting the safety profile of talquetamab as a potential tool in your MM patient management.

Following the repeat diagnostic workup presentation, an expert will lead the discussion, inviting the panel's input on the most appropriate treatment course for this patient.

The panel discussed resources to equip nurses in educating patients with multiple myeloma about their treatment options.

A team of multiple myeloma experts review a patient profile, offering preliminary insights and underscoring the importance of advanced practice providers in optimizing patient care.